Albert Seymour's most recent trade in Q32 Bio Inc. was a trade of 632,000 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 23, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 632,000 | 632,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 14,070 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 146,786 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 139,856 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc | Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 4,420 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2022 | 23,000 | 23,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc | Albert Seymour | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2022 | 14,000 | 14,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 128,000 | 128,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 8,710 | - | - | Restricted Stock Units | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 133,307 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 1,661 | 131,646 (0%) | 0% | 3.8 | 6,279 | Common Stock |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 78,000 | 78,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc | Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 13,000 | 13,000 | - | - | Restricted Stock Units |